SLS is trading 6.8% up at $9.11 today, extending a sharp multi-day rally despite a lack of fresh company-specific catalysts.
- The stock has climbed significantly from recent closes in the mid-$7 range, showing continued strength in this high-beta biotech name.
- There are no new press releases, FDA decisions, or analyst updates as of June 23, 2026, to fundamentally explain the move.
- The price action appears to be momentum-driven, notably outperforming broader indices which are currently trading down.